loading page

Proximity Extension assay-based proteomics studies in neurodegenerative disorders
  • +1
  • Burak Arioz,
  • Aysen Cotuk,
  • Cansu Yaka,
  • Sermin Genc
Burak Arioz
İzmir Biomedicine and Genome Center
Author Profile
Aysen Cotuk
İzmir Biomedicine and Genome Center
Author Profile
Cansu Yaka
Izmir Provincial Directorate of Health
Author Profile
Sermin Genc
İzmir Biomedicine and Genome Center

Corresponding Author:[email protected]

Author Profile

Abstract

Neurodegenerative diseases impact the structure and operation of the nervous system, causing progressive and irreparable harm. The absence of distinguishable symptoms in the early stages of neurodegenerative diseases makes diagnosis challenging. Additionally, it can be difficult to pinpoint the precise neurodegenerative disorder affecting a patient as the symptoms of these conditions frequently overlap. Numerous studies have shown that pathological changes occur years before clinical signs appear. Therefore, it is crucial to discover blood-based biomarkers for neurodegenerative diseases for easier and faster diagnosis. Proximity Extension Assay is a unique proteomics method that uses antibodies linked to oligonucleotides for quantifying proteins with real-time PCR. Proximity Extension Assay can identify even low-quantity proteins using a small volume of specimens with increased sensitivity compared to conventional methods. In this article, we reviewed the employment of Proximity Extension Assay technology to detect biomarkers or protein profiles for several neurodegenerative diseases.
19 Sep 2023Submitted to European Journal of Neuroscience
22 Sep 2023Submission Checks Completed
22 Sep 2023Assigned to Editor
26 Sep 2023Review(s) Completed, Editorial Evaluation Pending
27 Sep 2023Reviewer(s) Assigned
29 Oct 2023Editorial Decision: Revise Major
12 Nov 20231st Revision Received
14 Nov 2023Submission Checks Completed
14 Nov 2023Assigned to Editor
14 Nov 2023Review(s) Completed, Editorial Evaluation Pending
14 Nov 2023Reviewer(s) Assigned
15 Nov 2023Editorial Decision: Revise Major
20 Nov 20232nd Revision Received